MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus
Main finding · Prevalent CKDResult — go to the resultAdjusted odds ratio 1.76 95 % CI 1.05–2.96Authors' conclusion
This is the largest cross-sectional study showing that MASLD with and without coexisting significant fibrosis was associated, independently of potential confounders, with an increased risk of prevalent CKD and retinopathy in adults with T1DM.
Study context
- Population
- Adult outpatients with T1D
- Participants
- 1,409 outpatients
- Exposure
- MASLD with significant fibrosis vs MASLD without fibrosis vs no steatosis
- MASLD and significant fibrosisn = 93
- MASLD without fibrosisn = 578
- Without steatosisn = 738reference
- Outcome
- Prevalent CKD (estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m² or urine albumin/creatinine ratio ≥ 3.0 mg/mmol) or diabetic retinopathy
Methodological detailsmulticentre
- Multicentre
Main finding
Prevalent CKD
Adjusted odds ratio
1.76
95 % CI 1.05–2.96
MASLD and significant fibrosisvs Without steatosis
aOR 1.76 (95 % CI 1.05–2.96)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aOR (95 % CI) |
|---|---|
| Prevalent retinopathyBetween MASLD without fibrosis and Without steatosis · adjusted; estimate outside printed CI | 1.49 (1.13–1.46) |
Original publication
MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus. Diabetes Metab. Published 20 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →